Sign inJoin waitlistJoin the waitlist

Ciara O'Sullivan

Oncologist · Mayo Clinic College of Medicine and Science

Credentials: · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2012–2015
Internal Medicine
2005–2008
Medical School
2001–2005

Research

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Journal of Clinical Oncology · 2019 · 299 citations
Evolving standards of care and new challenges in the management of HER2-positive breast cancer
Review · Current Anthropology · 2020 · Last of 3 authors · 160 citations
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Journal of Clinical Oncology · 2023 · 98 citations

Kathryn Ruddy
20 papers
Matthew Goetz
12 papers
Tufia Haddad
8 papers
AW
Antonio Wolff
6 papers
CL
Charles Loprinzi
5 papers
IK
Ian Krop
5 papers
Karthik Giridhar
5 papers
Nancy Lin
5 papers
Stacy D'Andre
5 papers
Anna Weiss
4 papers
Daniela Stan
4 papers
Dawn Mussallem
4 papers

Grants

Developing, Implementing and Supporting NCI Clinical Trials and the National Cancer Trials Network (NCTN) in Breast Cancer and Developmental Therapeutics- A 5 Year Plan
National Cancer Institute · R50
Contact PI · $531.8K · Mayo Clinic Rochester
2024–2029

Clinical trials

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
Principal investigator · Withdrawn · Phase 2
Academic and Community Cancer Research United
2020–2022
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Principal investigator · Active not recruiting
Mayo Clinic
2017–2028
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Study chair · Active not recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2021–2035
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Site PI · Recruiting · Phase 3
BriaCell Therapeutics Corporation
2023–2028